secwatch.observer — SEC 8-K summary
======================================

Issuer:     CervoMed Inc. (CRVO)
CIK:        0001053691
Form:       8-K
Filed at:   2024-03-05T23:59:59+00:00
Accession:  0001437749-24-006546
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

CervoMed reports Phase 2a biomarker data: neflamapimod reduces GFAP, correlates with clinical outcomes in DLB
--------------------------------------------------------------------------------

- In pure DLB patients, neflamapimod reduced GFAP by mean 10.6 pg/mL vs 14.1 increase with placebo (p=0.04).
- GFAP reduction correlated with improvement on CDR-SB (r=0.542, p=0.036) in neflamapimod-treated pure DLB patients.
- Preclinical data from UCL shows neflamapimod enhances axonal transport in tauopathy mouse model of FTD.
- CEO states data support clinical efficacy in DLB and rationale for evaluating neflamapimod in frontotemporal dementia.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1053691/000143774924006546/0001437749-24-006546-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1053691/000143774924006546/crvo20240304_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-24-006546

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer